Dedicated to Innovation: Next-Generation Vanquish ME Device from BTL Aesthetics Reduces 53% More Fat Than its Predecessor

BOSTON, Dec. 6, 2016 /PRNewswire/ -- BTL Aesthetics today announced the release of a clinical evaluation proving that its BTL Vanquish ME device was effectively redesigned for more efficient, predictable and homogenous energy delivery to the targeted tissue. The result: Significantly better outcomes in abdominal fat thickness reduction, 53% higher, with BTL Vanquish ME versus BTL Vanquish.

"We are committed to providing our physician network and their patients with the most highly-advanced devices on the market," said Tomas Boleslavsky, Director of Clinical at BTL Aesthetics. "These clinical results, showing that our smartly-designed, next-generation device outperformed its predecessor, really speak to BTL Aesthetics' innovative approach and entrepreneurial spirit."

Background:

BTL Vanquish launched in 2013, was a breakthrough device for noninvasive fat reduction. Not stopping there, BTL Aesthetics' commitment to an innovative approach quickly resulted in the development of BTL Vanquish ME (Maximum Energy), which debuted in 2015. BTL Vanquish ME is a physician-favored fat reduction treatment that is FDA-cleared for the circumferential reduction of the abdomen and thighs. The treatment was also recently shown, in a peer-review study published in the Journal of Drugs and Dermatology, that it treats more fat faster—and over a much larger area—than its competitors on the market. BTL Vanquish and BTL Vanquish ME are the only radiofrequency devices on the US Aesthetic market that allow for non-contact, hands-free treatment of subcutaneous fat.

About the Clinical Study:

The multi-center study, conducted by Drs. Nicole Hayre, Peter Jenkin and Melanie Palm, sought to compare clinical outcomes of a noninvasive selective radiofrequency (RF) field device (BTL Vanquish ME) with its predecessor (BTL Vanquish). A total of 36 subjects with BMIs under 30 but above 24, were randomly assigned to be treated in Group A (BTL Vanquish ME) or Group B (Vanquish) to obtain a side-by-side comparison of the devices' efficacies. Each subject received four, once-weekly, 45-minute treatments with their group's determined device. Measurements of subjects' abdominal fat were taken prior to the first treatment and again four weeks after finishing the final treatment. Subjects had also been instructed to maintain their usual diet and lifestyle throughout the duration of the study.

Results

Abdominal fat layer thickness reduction at 30 days post treatment was the primary outcome measurement in the study as measured by ultrasound. The degree in fat layer thickness between Group A and B was statistically significant (p<0.008), and data showed that fat for Group A (BTL Vanquish ME) and Group B (BTL Vanquish) was reduced by 29.5% and 15.2%, respectively. That represents a 53% higher reduction of abdominal fat layer thickness with Group A than for those in Group B. Every subject in the study showed a reduction in the abdominal fat layer thickness.

-       Group A: Reduction ranged from 2.0 to 6.6 mm (average of 4.17 ±1.42 mm)
-       Group B: Reduction ranged from .07 to 10.4 mm (average of 2.72 ± 2.21 mm)

The standard deviation of ultrasound measurements in Groups A and B were 1.42 mm and 2.21 mm, respectively—and this reduction in standard deviation of fat reduction measurements in Group A vs Group B is evidence that the BTL Vanquish ME™ provides more consistent performance.

Finally, using the measured reduction in fat layer thickness and the treatment surface area of the applicator (2100 cm² or 325.5 square inches), a reduction of 0.876 liter (0.23 liquid gallon) and 0.571 liter (0.15 liquid gallon) of fat were calculated for Groups A and B, respectively.  (Volume lost = fat layer thickness reduction x effective area or spot size of the applicator (2100 cm2; 325.5 square inches).  This assumes an homogenous response to treatment.

Further speaking to its uniqueness in the market, the BTL Vanquish ME device holds three patents: One, granted in 2013, protects the non-contact method of adipose tissue treatment. The second, issued in September 2016, is for the feedback power control device for non-invasive treatment of skin and human tissue. The third—issued in October—refers to a new method for treating subcutaneous tissue that positions one or more applicators adjacent to the skin of a patient, but not touching the skin or in need of continual movement by the applicator. These applicators, which transmit electromagnetic energy into the skin where it can be used for subcutaneous tissue treatment, may also be used for tightening the skin and for remodeling collagen tissue in the subcutaneous tissue. Additionally, airflow can be provided between the applicator and the skin by positioning an air mover (attached or made part of the applicator) close to the skin.

BTL Vanquish ME treatments are available through a network of licensed physicians and medically supervised spas. Visit www.btlvanquishme.com to find a physician for treatment.

About BTL Industries

Founded in 1993, BTL has grown to become one of the world's major manufacturers of medical and aesthetic equipment. With over 1,100 employees located in more than 53 countries, BTL has revolutionized the way to offer the most advanced non-invasive solutions for body shaping, skin tightening & other medical aesthetic treatments. BTL Aesthetics' brands include BTL Vanquish ME, BTL Exilis Ultra, and BTL Cellutone.

Additional information can be found at http://www.btlaesthetics.com.

Logo - http://photos.prnewswire.com/prnh/20160425/359513LOGO

SOURCE BTL Aesthetics